Adma Biologics Inc. (ADMA) Sees Unusually-High Trading Volume
Adma Biologics Inc. (NASDAQ:ADMA) shares saw unusually-high trading volume on Tuesday . Approximately 179,899 shares changed hands during mid-day trading, an increase of 248% from the previous session’s volume of 51,699 shares.The stock last traded at $7.13 and had previously closed at $6.68.
ADMA has been the subject of a number of recent analyst reports. Maxim Group decreased their price objective on shares of Adma Biologics from $24.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, July 25th. Raymond James Financial Inc. lowered shares of Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 1st.
The stock’s 50 day moving average price is $5.85 and its 200 day moving average price is $6.54. The company’s market capitalization is $91.75 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/adma-biologics-inc-adma-sees-unusually-high-trading-volume.html
Adma Biologics (NASDAQ:ADMA) last announced its earnings results on Friday, August 12th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.11. Adma Biologics had a negative return on equity of 1,293.57% and a negative net margin of 231.85%. On average, equities research analysts expect that Adma Biologics Inc. will post ($1.76) earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Iguana Healthcare Management LLC bought a new position in shares of Adma Biologics during the second quarter worth $744,000. Franklin Resources Inc. increased its stake in Adma Biologics by 41.0% in the first quarter. Franklin Resources Inc. now owns 359,499 shares of the company’s stock worth $2,908,000 after buying an additional 104,500 shares during the period. Sabby Management LLC acquired a new stake in Adma Biologics during the second quarter worth $595,000. UBS Oconnor LLC increased its stake in Adma Biologics by 111.3% in the second quarter. UBS Oconnor LLC now owns 71,174 shares of the company’s stock worth $423,000 after buying an additional 37,497 shares during the period. Finally, Spark Investment Management LLC increased its stake in Adma Biologics by 126.8% in the second quarter. Spark Investment Management LLC now owns 31,300 shares of the company’s stock worth $186,000 after buying an additional 17,500 shares during the period. 73.91% of the stock is owned by institutional investors.
Adma Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for Adma Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adma Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.